ATE153536T1 - Hiv-induzierte synzytien blockierender anti-cd-4- antikörper - Google Patents

Hiv-induzierte synzytien blockierender anti-cd-4- antikörper

Info

Publication number
ATE153536T1
ATE153536T1 AT92903295T AT92903295T ATE153536T1 AT E153536 T1 ATE153536 T1 AT E153536T1 AT 92903295 T AT92903295 T AT 92903295T AT 92903295 T AT92903295 T AT 92903295T AT E153536 T1 ATE153536 T1 AT E153536T1
Authority
AT
Austria
Prior art keywords
synzytia
hiv
antibodies
induced
blocking anti
Prior art date
Application number
AT92903295T
Other languages
English (en)
Inventor
Linda C Burkly
Patricia L Chisholm
David W Thomas
Margaret D Rosa
Joseph J Rosa
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc filed Critical Biogen Inc
Application granted granted Critical
Publication of ATE153536T1 publication Critical patent/ATE153536T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT92903295T 1990-11-27 1991-11-27 Hiv-induzierte synzytien blockierender anti-cd-4- antikörper ATE153536T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US61854290A 1990-11-27 1990-11-27

Publications (1)

Publication Number Publication Date
ATE153536T1 true ATE153536T1 (de) 1997-06-15

Family

ID=24478147

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92903295T ATE153536T1 (de) 1990-11-27 1991-11-27 Hiv-induzierte synzytien blockierender anti-cd-4- antikörper

Country Status (13)

Country Link
US (1) US5871732A (de)
EP (1) EP0512112B1 (de)
JP (5) JPH05505112A (de)
AT (1) ATE153536T1 (de)
AU (1) AU662891B2 (de)
CA (1) CA2073031C (de)
DE (1) DE69126301T2 (de)
DK (1) DK0512112T3 (de)
ES (1) ES2101834T3 (de)
GR (1) GR3024274T3 (de)
HK (1) HK1007686A1 (de)
OA (1) OA10079A (de)
WO (1) WO1992009305A1 (de)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5651970A (en) * 1993-03-19 1997-07-29 Allen; Allen D. Method for inhibiting disease associated with the human immunodeficiency virus through the use of monoclonal antibodies directed against anti-self cytotoxic T-lymphocytes or their lytics
DE4435950A1 (de) * 1994-10-07 1996-04-11 Hoechst Ag Copolymerisate mit cyclischen oder polycyclischen Monomeren mit einer speziellen Isomerenverteilung und deren Einsatz in Beschichtungsmitteln
US5961976A (en) * 1996-06-03 1999-10-05 United Biomedical, Inc. Antibodies against a host cell antigen complex for pre- and post-exposure protection from infection by HIV
WO1998058966A1 (en) * 1997-06-24 1998-12-30 Norman Godin A composition for specific immunoprotection and method for obtaining said composition
US6420545B1 (en) * 1999-05-24 2002-07-16 The Trustees Of The University Of Pennsylvania CD4-independent HIV envelope proteins as vaccines and therapeutics
JP2003533968A (ja) * 1999-09-03 2003-11-18 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド 免疫グロブリンスーパーファミリーポリヌクレオチド、ポリペプチド、および抗体
AU2265701A (en) * 1999-12-16 2001-06-25 Tanox, Inc. Anti-hiv-1 conjugates for treatment of hiv disease
CN101152574A (zh) * 2002-09-27 2008-04-02 唐纳士公司 用于预防和治疗获得性免疫缺陷综合症的协同组合物
EP1460088A1 (de) * 2003-03-21 2004-09-22 Biotest AG Humanisierter Antikörper gegen CD4 mit immunsuppressiven Merkmalen
WO2007094983A2 (en) * 2006-02-03 2007-08-23 Tanox, Inc. Methods and compositions for the inhibition of hiv infection of t cells
AU2007286451A1 (en) * 2006-08-17 2008-02-21 F. Hoffmann-La Roche Ag A conjugate of an antibody against CCR5 and an antifusogenic peptide
TW200817438A (en) * 2006-08-17 2008-04-16 Hoffmann La Roche A conjugate of an antibody against CCR5 and an antifusogenic peptide
US20090143288A1 (en) * 2007-03-13 2009-06-04 Roche Palo Alto Llc Peptide-complement conjugates
US20130195881A1 (en) 2007-04-27 2013-08-01 Sanjaya Singh Potent, stable and non-immunosuppressive anti-cd4 antibodies
CL2008002092A1 (es) * 2007-07-20 2009-05-29 Hoffmann La Roche Conjugado que contiene dos o mas peptidos antifusogenicos y un anticuerpo anti-cd-4; metodo de produccion; composicion farmaceutica que lo comprende; polipeptidos antifusogenicos y uso del conjugado para tratar infecciones viricas.
CN102027016A (zh) * 2008-03-13 2011-04-20 生物测试股份公司 一种治疗疾病的试剂
RU2540018C2 (ru) * 2008-03-13 2015-01-27 Биотест Аг Средство для лечения заболевания
WO2009121690A1 (en) * 2008-03-13 2009-10-08 Biotest Ag Agent for treating disease
CA2732508C (en) 2008-08-11 2016-03-15 Nektar Therapeutics Multi-arm polymeric alkanoate conjugates
KR20110061630A (ko) * 2008-09-29 2011-06-09 바이오테스트 아게 질병 치료용 조성물
EP2246364A1 (de) * 2009-04-29 2010-11-03 Pierre Fabre Médicament Antikörper gegen CXCR4 zur Behandlung von HIV
GB0920944D0 (en) 2009-11-30 2010-01-13 Biotest Ag Agents for treating disease
EP3187585A1 (de) 2010-03-25 2017-07-05 Oregon Health&Science University Cmv-glycoproteine und rekombinante vektoren
US10894087B2 (en) 2010-12-22 2021-01-19 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
US20130331443A1 (en) 2010-12-22 2013-12-12 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of taxane-based compounds
US20140088021A1 (en) 2011-05-27 2014-03-27 Nektar Therapeutics Water-Soluble Polymer-Linked Binding Moiety and Drug Compounds
PL2691530T3 (pl) 2011-06-10 2019-02-28 Oregon Health & Science University Glikoproteiny i rekombinowane wektory CMV
CN102321653B (zh) * 2011-07-18 2013-11-20 清华大学 人鼠嵌合型cd4质粒及其多抗在抑制hiv感染中的应用
US20130189754A1 (en) 2011-09-12 2013-07-25 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
WO2014100139A1 (en) 2012-12-18 2014-06-26 The Rockefeller University Glycan-modified anti-cd4 antibodies for hiv prevention and therapy
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
EP2873423B1 (de) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
JP6716544B2 (ja) 2014-09-16 2020-07-01 ユナイテッド・バイオメディカル・インコーポレーテッドＵｎｉｔｅｄ Ｂｉｏｍｅｄｉｃａｌ Ｉｎｃｏｒｐｏｒａｔｅｄ 競合的ｈｉｖ侵入阻害を媒介するｃｄ４に対するモノクローナル抗体によるｈｉｖ感染の処置および機能的治癒
EP3069730A3 (de) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
EP3072901A1 (de) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
CA2987871A1 (en) 2015-06-01 2016-12-08 Medigene Immunotherapies Gmbh Method for generating antibodies against t cell receptor
AU2016273213B2 (en) 2015-06-01 2019-03-14 Medigene Immunotherapies Gmbh T cell receptor library
US9925258B2 (en) 2015-10-02 2018-03-27 International Aids Vaccine Initiative Replication-competent VSV-HIV Env vaccines
KR20180089446A (ko) 2015-12-23 2018-08-08 메디진 이뮤노테라피스 게엠바하 수지상 세포 조성물
MX2019001814A (es) 2016-08-13 2019-07-08 Ubi Ip Holdings Tratamiento y remision virologica sostenida de infeccion de vih mediante anticuerpos a cd4 en pacientes estabilizados con haart.
CN112175087B (zh) * 2019-07-02 2022-05-13 深圳市迈加瑞生物技术有限公司 一种抗CD4和TGFβ的双特异性抗体、其药物组合及其用途
US20210054054A1 (en) * 2019-08-19 2021-02-25 The Rockefeller University Engineering ph-dependent antigen binding activity into anti-hiv antibodies with improved pharmacokinetics
WO2021062546A1 (en) * 2019-10-01 2021-04-08 Taimed Biologics Inc. Use of ibalizumab for the treatment of hiv-2 infection
CN112500491B (zh) 2020-12-18 2022-04-08 深圳市迈加瑞生物技术有限公司 一种特异性中和辅助性T细胞TGF-β信号的双特异性抗体、其药物组合及其用途
TW202321457A (zh) 2021-08-04 2023-06-01 美商薩那生物科技公司 靶向ｃｄ４之病毒載體之用途
WO2023114949A1 (en) 2021-12-16 2023-06-22 Sana Biotechnology, Inc. Methods and systems of particle production
WO2023133595A2 (en) 2022-01-10 2023-07-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023150647A1 (en) 2022-02-02 2023-08-10 Sana Biotechnology, Inc. Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023193015A1 (en) 2022-04-01 2023-10-05 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
WO2024026377A1 (en) 2022-07-27 2024-02-01 Sana Biotechnology, Inc. Methods of transduction using a viral vector and inhibitors of antiviral restriction factors
WO2024044655A1 (en) 2022-08-24 2024-02-29 Sana Biotechnology, Inc. Delivery of heterologous proteins
WO2024064838A1 (en) 2022-09-21 2024-03-28 Sana Biotechnology, Inc. Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4515895A (en) * 1979-04-26 1985-05-07 Ortho Pharmaceutical Corporation Hybrid cell line for producing monoclonal antibody to human helper T cells
US4381295A (en) * 1979-04-26 1983-04-26 Ortho Pharmaceutical Corporation Monoclonal antibody to human helper T cells and methods of preparing same
US4652447A (en) * 1979-04-26 1987-03-24 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human helper T cells
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4653020A (en) * 1983-10-17 1987-03-24 International Business Machines Corporation Display of multiple data windows in a multi-tasking system
NZ215865A (en) * 1985-04-22 1988-10-28 Commw Serum Lab Commission Method of determining the active site of a receptor-binding analogue
JPH02501192A (ja) * 1987-09-04 1990-04-26 バイオジェン インコーポレイテッド 可溶性ｔ４蛋白を製造するためのｄｎａ配列、組換ｄｎａ分子および方法
US4908203A (en) * 1987-09-09 1990-03-13 Johnson & Johnson Method for inducing HIV neutralizing antibodies using an internal image idiotope
AU631357B2 (en) * 1987-10-14 1992-11-26 United States of America, as represented by the Secretary, U.S. Department of Commerce, The New anti-receptor peptides and therapeutic agents
WO1990004978A1 (en) * 1988-11-01 1990-05-17 Becton Dickinson And Company Method of directing immune response to a viral binding site
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies

Also Published As

Publication number Publication date
EP0512112B1 (de) 1997-05-28
ES2101834T3 (es) 1997-07-16
US5871732A (en) 1999-02-16
DK0512112T3 (da) 1997-09-29
AU9154391A (en) 1992-06-25
JPH05505112A (ja) 1993-08-05
JP4642035B2 (ja) 2011-03-02
JP2007175055A (ja) 2007-07-12
JP2002356499A (ja) 2002-12-13
OA10079A (en) 1996-12-18
DE69126301T2 (de) 1998-01-02
EP0512112A1 (de) 1992-11-11
JP2007151556A (ja) 2007-06-21
CA2073031A1 (en) 1992-05-28
GR3024274T3 (en) 1997-10-31
CA2073031C (en) 2002-10-01
AU662891B2 (en) 1995-09-21
DE69126301D1 (de) 1997-07-03
JP2005041859A (ja) 2005-02-17
WO1992009305A1 (en) 1992-06-11
HK1007686A1 (en) 1999-04-23

Similar Documents

Publication Publication Date Title
ATE153536T1 (de) Hiv-induzierte synzytien blockierender anti-cd-4- antikörper
ATE86636T1 (de) F antigene vom menschlichen immunodefizienz-virus und deren verwendungen.
Okamoto et al. Purification and characterization of interferon-γ-inducing molecule of OK-432, a penicillin-killed streptococcal preparation, by monoclonal antibody neutralizing interferon-γ-inducing activity of OK-432
DK0494294T3 (da) Bakterielle stressproteiner
DK1025849T5 (da) Fremgangsmåder til påvisning og behandling af individer, som har unormale celler, som udtrykker HLC-A2/tyrosinasepeptid-antigener
JO1671B1 (en) New ways to diagnose tuberculosis
ATE142262T1 (de) Gegen das menschliche immunschwäche-virus gerichtetes immunpräparat
AU6461594A (en) Induction of protection against viral infection
Panem et al. Renal deposition of alpha interferon in systemic lupus erythematosus
ATE239502T1 (de) Impfung mit peptiden von mhc klasse ii molekülen zur behandlung von autoimmunkrankheiten
EP0491888A4 (en) Immunotherapeutic compositions for treating and preventing aids, arc and hiv infection
PRÜMMER et al. Anti-interferon-γ antibodies in a patient undergoing interferon-γ treatment for systemic mastocytosis
DE69433057D1 (de) Peptide zur verwendung bei der impfung und induktion neutralisierender antikörper gegen das menschliche immunschwäche-virus
Tyring et al. Antiviral action of murine interferons on heterologous cells
RU93004854A (ru) Пептиды для вакцинации и индукции нейтрализующих антител против вируса иммунодефицита человека

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time